Pitt Street Research sees strong upside in Prescient Therapeutics as one of the most advanced oncology companies on the ASX .

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, highlighting notable ocular toxicities and missed opportunities for dosing ...

This study provides valuable findings regarding potential correlates of protection against the African swine fever virus. The evidence supporting the claims is solid, although analysis using a higher ...

Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for its Phase 2a trial of PTX-100 for patients ...

The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...

Nasus Pharma has filed to raise $11M in an IPO of its ordinary shares, according to SEC F-1 registration. Read why my outlook ...

The rapid lateral flow assay from Lumos Diagnostics distinguishes bacterial and nonbacterial respiratory infections using a drop of blood.

Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...

The benchmarking report used a rigorous methodology to ensure results reflected ICON’s true impact and performance in the competitive phase 1 landscape. ISR screened participants to ensure relevance ...

University of New Mexico researchers have received funding to launch an early-stage clinical trial of a vaccine engineered to ...

Esketamine monotherapy is linked to greater 28-day symptom reduction in treatment-resistant depression vs placebo, new research shows.